On Thursday, 26 November, the European Commission decided to impose €60.5 million in fines on the pharmaceutical companies Teva (Israel) and Cephalon (United States) because these companies agreed to delay the market entry of a cheaper generic version of Cephalon’s medication for sleep disorders modafinil after the expiry of Cephalon’s main patents.
The agreement—concluded well before Cephalon became a subsidiary of Teva—“violated EU antitrust rules and caused substantial...